
ANNUAL REPORT 2020







Words from THE PRESIDENT



Mr Robert Hensler Chairman of the Foundation Board

«Removing the injustice that affects children with cancer»

This 2020 report gives you a special insight into the activities of the CANSEARCH Foundation in the context of the COVID 19 pandemic. Each of us has been deeply affected in our personal and professional lives by the significant changes brought about by this global health crisis.

Children suffering from cancer and other blood diseases have been no exception, as they too have experienced the effects of this unique situation, which has resulted in many complications and restrictions in their treatment.

Their daily lives were punctuated by visits to the hospital only by their parents, to the exclusion of all other family members, by constant vigilance for themselves and their loved ones to protect themselves from the coronavirus, and by a high degree of resilience to overcome the difficulties associated with hospital services operating under tight deadlines during successive waves of peaks in Covid cases.

This extreme situation, however, provided a better understanding to the general public of how medical research works, its great financial needs and successes, but also the challenges it faces, in order to save lives.

As my term of office as President of the Board and that of Ms Céline Denizot as Vice-President come to an end statutorily, at the dawn of a new era, I would like to express my gratitude to all those who have contributed to the success of the Council. As we enter the year 2021, which will celebrate CANSEARCH's 10th anniversary, we are proud to have witnessed the multiplication of projects: from less than a dozen in 2011, 24 studies have just been validated by our Scientific Committee, which fills us with joy and optimism, particularly during this complicated health period.

Thanks to your faithful and generous support, paediatric onco-haematology and in particular pharmacogenomics has been able to progress. Our results in this field regarding the adaptation of the Busulfan dose to the child's genetics during conditioning treatment prior to stem cell transplantation for leukaemia are established and scientifically recognised, as demonstrated by the large number of publications obtained. They have allowed the opening of another very important project (BUGENES), which should validate this result in a prospective manner and which constitutes the culmination of 10 years of research in this field.

We are also pleased to be able to hand over the reins of the foundation to Sébastien Joliat, the new president, and to welcome Patricia Hubscher Eichenberger and Guerric Canonica as new members from January 2021, alongside Maurice Machenbaum and Phil Lenz, who are already members. We wish them every success in the years to come!

Thanks to the magnificent support of our generous donors, partners and volunteers, Professor Marc Ansari, the members of the Foundation's General Secretariat, and the expertise of our Foundation Board and Committee members, our researchers can dedicate their advanced scientific skills to improving the understanding of the disease and to finding treatments that bring less toxicity and fewer side effects to children. We thank them warmly and deeply for their faithful support.

Words FROM THE FOUNDER & DIRECTOR



Professor Marc Ansari

Founder and Director of the CANSEARCH Foundation Head of the Paediatric Oncology and Haematology Unit of the HUG

«Helping more children recover from cancer and blood diseases»

A big thank you to everyone, and in particular to our President, Mr Robert Hensler and our Vice-President, Ms Céline Denizot, whose statutory mandates on our Board came to an end this year, for the valuable skills they have brought to CANSEARCH for almost 10 years. We are very pleased that they have agreed to join our Honorary Committee as President for Mr. Hensler, and our Advisory Committee as a member for Ms. Denizot.

Thanks to the immense generosity of our donors and partners, whom I would like to thank from the bottom of my heart, and to their faithful trust for which we are extremely grateful, the CANSEARCH Foundation has been able to develop numerous research projects for children over the past decade.

This Annual Report, which refers to the year 2020, will give you an overview of the important developments achieved during the past year by the CANSEARCH research platform in paediatric oncology and haematology at the University of Geneva (the Platform), which was set up in collaboration with the Geneva University Hospitals (HUG) and the Faculty of Medicine of the University of Geneva in 2011.

These last twelve months have not been easy, due to covid-19: closure of the laboratory from mid-March onwards for almost two months, partial teleworking in order to respect health regulations, general slowdown of our patient recruitment activities involving several international partners strongly impacted by the crisis, these were only some of the direct effects of the pandemic on our activities within the research platform.

However, the solidarity, agility and resilience shown by our researchers and all the people with whom we collaborate have enabled our research projects to continue and to progress favourably.

The CANSEARCH Foundation & some figures on CHILDHOOD CANCER

Created in 2011 in collaboration with the **University Hospi**tals of Geneva (нис) and the **University of Geneva** Supports research to improve the understanding and treatment of childhood cancer and blood diseases

Set up the **first research platform in paediatric onco-haematology** with more than 20 researchers, laboratory technicians and students

Focuses on **personalised medicine** by looking in the genes for how disease develops and **how to tailor treatments to the genetics** of young patients

1ST CAUSE OF MORTALITY BY DISEASE in children Between **250 AND 300 NEW** cases diagnosed per year in 0-15 year olds

50% of diagnoses concern CHILDREN BETWEEN 1 AND 4 YEARS OF AGE

MORE THAN 80% OF CHILDREN CAN BE SAVED

(compared to 20% 50 years ago)

LESS THAN 2% of funds raised for cancer research are allocated to paediatric cancers

About 2/3 OF CHILDREN DEVELOP SEQUELLS IN ADULTH

Afonso

« My biggest dream is to be able to go back to school, see my friends and lead a normal life »

•

The Financial **ASPECTS**



Your generosity and unwavering support during the year 2020 has enabled the CANSEARCH Foundation to fund the salaries of our researchers and the laboratory equipment necessary to continue the Platform's projects.

A very big thank you to all of you who, thanks to your donations and actions, allow us to continue our mission to fight childhood cancers.

Phil Lenz Treasurer of the Foundation Board

Income statement for the year 2020

	2020	2019
	CHF	CHF
INCOME	1 639 660	4 244 318
Grants, private donations	1 639 660	4 231 625
Subsidies and financial aid, city of Geneva	-	12 693
DIRECT EXPENSES	2 225 540	1 714 498
Laboratory expenses	205 293	219 519
Salaries, wages & other research	1 958 773	1 466 776
expenses Support to research	45 300	-
Fixed assets depreciations	16 174	28 203
PROFIT FROM OPERATIONS	-585 880	2 529 820
GENERAL AND ADMINISTRATION EXPENSES	334 569	678 975
Events costs	1 354	373 916
Salaries and other benefits - administration	224 810	224 636
Scientific Committee fees	12 274	9 110
General and administration expenses	77 893	54 612
Accouting, audit and consultancy fees	18 237	16 702
EARNINGS BEFORE INTERESTS AND TAXES (DEBIT)	-920 449	1 850 844
FINANCIAL RESULT	-32 041	-16 381
Banks fees	-1 022	-4 980
Other financial revenues	98	173
Exchange variations	-31 117	-11 574
EARNINGS BEFORE FUND AFFECTATION	-952 490	1 834 464
FUNDS CONTRIBUTIONS	-952 490	-1 834 464
Contribution to the research fund	-	-1 849 735
Contribution to the fixed assets depreciations fund	6 910	-12 475
./. Fixed assets depreciations fund reallocation	-	1 031
./. Use of the fixed assets depreciations fund	-959 400	26 715
NET PROFIT	0	0

Composition of **BOARDS & COMMITTEES**

 \ll Let's be active for Cansearch, because together we are stronger and we can go further \gg

The CANSEARCH Foundation would be nothing without the skills and commitment of the members of its Boards and Committees, its General Secretariat (the Bureau) and its permanent volunteers.

Members of the Foundation Board



Mr. Robert Hensler, President (until 31.12.2020. Chairman of the Honorary Committee from 1 January 2021)



Céline Denizot, Vice President (until 31.12.2020. Member of the Advisory Board from 1 January 2021)



Phil Lenz, Treasurer



Maurice Machenbaum, Member

Members of the Scientific Committee



Prof. Jakob Passweg, President



Prof. Marina Cavazzana



Prof. Urs A. Meyer





Prof. Sylvain Baruchel

Prof. Roderick Skinner

Advisory Committee



Thomas Goossens



Patricia Hubscher Eichenberger, (Member of the Board of Foundation from 01.01.2021)



Gian Cla Pinösch

General Secretariat



Prof. Marc Ansari, Director



Patricia Legler, Secretary General



Nathalie Martens Jacquet, Donor Manager

Permanent volunteers



Valérie Steck



Cathy Wintsch



Alix Rivoire



Stephanie Ansari

Honorary Committee


Mr. Robert Hensler, President (from 01.01.2021), Mrs. Martha ARGERICH, Mr. Guerric CANONICA (Member of the Foundation Board from March 2021), Mr. Guy DEMOLE, Mr. Léonard GIANADDA, Mr. Romain GROSJEAN, Mrs. Carole HUBSCHER, Families Frédy and Franco KNIE, Mr Raymond LORETAN, Mrs Michèle MAUS, Mr Olivier MAUS, Mr Pierre MOTTU, Mr Claude PICASSO, Mr Stan WAWRINKA, Mr Jean ZERMATTEN, ZEP

«More than 20 researchers, laboratory technicians and students because research requires increasingly complex and diverse skills»




From left to right: Yohann Sarmiento, Dr Tiago Nava, Khalil Benhassine, Dr André Von Büren, Rodolfo Lo Piccolo, Dr Fabienne Gumy Pause, Dr Frédéric Baleydier, Nadia Gatti, Fanny Muet, Shannon Robin, Simona Mlakar, Dr Fanette Bernard, Vid Mlakar, Veneranda Mattiello, Laurence Lesne, Nelly Hafner Benichou, Denis Marino, Rao Chakradhara Uppugunduri, Dr Nicolas Waespe, Sven Strebel, Mary Boudal-Khoshbeen, Prof. Dr. Marc Ansari.

«More than 20 research projects to optimise results for sick children»



Pharmacogenomics projects **INTERVIEW**



Dr Tiago Nava

Deputy Director of the CANSEARCH research platform in paediatric oncology and haematology at the University of Geneva



Dr Rao Chakradhara S. Uppugunduri Head of basic research at the CANSEARCH research platform in paediatric oncology and haematology at the University of Geneva

What are the research projects of the CANSEARCH research platform in paediatric oncology and haematology at the University of Geneva (the Platform)?

In 10 years, the Platform has developed 6 research axes in addition to its own biobank: individualised therapy, stem cell transplantation, neuroblastoma, liver tumours, brain tumours and non-malignant diseases.

Our main pharmacogenomics (individualised therapy/personalised medicine) project to tailor the dose of chemotherapy to the child's genetics in stem cell transplantation for certain leukaemias has grown and has been subdivided into 14 subprojects during 2020. This retrospective study has proven its validity and now needs to be validated for acute lymphoblastic leukaemia (FORUM project), myeloid leukaemia (MYECHILD project) and neuroblastoma, and then demonstrate its validity prospectively (BUGENES study). We are pleased to be able to start this first European prospective paediatric pharmacogenomic study of Busulfan in 2021.

Together, these studies aim to better understand the effects of certain drugs on genes to fight leukaemia, and to unravel the mysteries of how these genes function under the effect of the substances in these treatments. The ultimate goals are to reduce treatment-related toxicity and increase the survival of our little patients. «Pharmacogenomics allows us to understand the effect of drugs and treatments on the genetics of our young patients»

«The diversity of our studies and projects allows us to understand different types of cancers»

Dr Nava and Dr Uppungunduri

What have been the main developments in the pharmacogenomics project, which is the Platform's flagship project, over the past year?

Based on the results obtained retrospectively on the dose of Busulfan to be administered before stem cell transplantation to treat certain leukaemias, our model for predicting this dose in children and adolescents for the future, this time in a prospective and randomised manner, was tested and improved during the year 2020 (**BUGENES** study). This was made possible by clinical and genetic data obtained from more than 400 young patients who received different combinations of drugs with Busulfan while undergoing transplant treatment, recruited from different medical centres in 5 different countries in addition to Switzerland, including France, Canada, Denmark, Italy and Australia.

This large multicentre study, whose protocol was submitted to the Research Ethics Committee of the Canton of Geneva in September 2020, will compare the efficacy of the administration of the chemotherapeutic agent Busulfan in a new way, by adapting it to the child's genetics, with the current model which does not yet take genetics into account. A submission for scientific publication of this study has also been planned for early 2021.

Can you tell us about other projects related to the pharmacogenomics project?

For the pharmacogenomics part of our **FORUM** project, an additional 100 patients could be recruited in 2020, bringing the total number of DNA samples obtained from these patients to 400 so far (out of a total of 1000 patients recruited for the overall **FORUM** study including clinical aspects).

DNA from 200 of these patients has been sent to Campus Biotech in Geneva, which is sequencing this DNA for us, and we expect to have sequenced all 400 patients by the end of 2020. The Swiss Institute of Bioinformatics (SIB), which is also our partner, will then analyse this gene expression data at the cellular level in collaboration with the Platform.

It should be noted here that obtaining DNA samples from children with cancer from numerous medical centres around the world is a major task for our platform. This explains why obtaining a large number of these samples represents a significant advance.

Several scientific papers from the **FORUM** project have been submitted and accepted for publication in the prestigious Journal of Clinical Oncology during 2020, and we are hopeful that these will be published during 2021. This is a very important recognition of our researchers' work.

For the **MYECHILD** myeloid leukaemia project, the main development in 2020 was the inclusion of our country, Switzerland, in the study protocol. In addition, the first DNA samples from patients recruited in the UK, France and Australia for this project have arrived at the biobank (BAHOP).

It should be added that the aim of these FORUM

and **MYECHILD** studies is to validate our scientific hypotheses in homogeneous cohorts since we have already demonstrated the links between pharmacogenomics (study of the effects of genes on drug response) and pharmacokinetics (study of the fate of an active substance of a drug after its administration in the body) retrospectively in non-homogeneous patient cohorts, and the links with child survival.

These studies also allow us to compare different substances administered to children to treat them, such as busulfan, treosulfan or cyclosporine, in order to assess the degree of their effectiveness. Finally, the study of different toxicities that may arise from current treatments, such as graft-versus-host disease or sinusoidal obstruction syndrome, is also an important part of our work.

We are also conducting a project focused on assessing the cytotoxicity of lymphoblastoid cell lines exposed to different doses of Busulfan and Treosulfan. Our aim is to determine which individual lymphoblastoid cell line is most sensitive or resistant to chemotherapy and then to understand whether this sensitivity is related to their genetic profile by examining the expression levels of all genes within their genome (also known as a genome-wide association study).

The identified genetic polymorphisms will be clinically evaluated in the **MYECHILD** and **FORUM** cohorts to determine the causes of this difference in cell survival.

Are there any other studies underway?

Yes, we also have a project on liver cancer, another on neuroblastoma, another on brain tumours, a study on stem cell transplants in collaboration with the EPFL, and a new study on sickle cell disease, the main developments of which I will give you below.



The RELIVE registry project (Relapse of Liver Cancer – www.reliveinternational.net) By setting up a registry to collect data on treatments used, relapses and side effects in a retrospective manner, the resulting vision will allow the identification of new therapeutic approaches and the construction of a new clinical treatment protocol for these children.

As liver cancer is very rare in children (1% of all paediatric cancers), this makes it all the more important to bring together the international experts formed around this study ("Children's Hepatic International Collaboration - CHIC").

The preparation of the documentation to create this registry allowed its submission to the Swiss Ethics Committee in 2020, which approved it. The registry is now being opened in other countries (USA, Canada, Japan, Australia and Europe) and we are pleased with the collaboration formed around it between the Children's Oncology Group (COG) in America, the International Society of Paediatric Oncology for Liver Cancer (SIOPEL), the Children's Hepatic International Collaboration (CHIC), and the Japan Children's Cancer Group.

The Neuroblastoma Project - Dr Fabienne Gumy Pause and Vid Mlakar

Neuroblastoma is the most common cancer of the young child and also one of the most aggressive, contributing significantly to the death of children under 5 years old. This disease has, in its advanced forms, a survival rate of less than 50%, and this despite a very intense multimodal treatment. As the development of new therapeutic strategies has therefore become a priority in the field of neuroblastoma, Cansearch laboratory researchers have been working on a new approach that aims to study DNA repair mechanisms as a therapeutic target.

In recent years, Fabienne and Vid have been studying the efficacy of a small molecule called PRIMA-1MET in the treatment of neuroblastoma. The results obtained on neuroblastoma cell lines being very encouraging, they are continuing their work by studying the efficacy of this molecule in an "in vivo" model, in particular in combination with chemotherapies used in the standard treatment of this disease. In parallel, other experiments are underway to better understand the molecular mechanisms involved in PRIMA-1MET-induced tumour cell death.

The Brain Tumour Project (HGG-CNS Registry) - Dr André Von Büren

This neuro-oncology project, led by Dr. André Von Büren, aims to create a registry of young children under 3 years of age with the very rare pediatric high-grade glioma (HGG) in collaboration with medical and scientific partners in Europe, mainly in Switzerland, Germany and Austria.

The epidemiological, clinical and molecular data collected will provide information on the frequency of the disease, the specific histopathological subgroups and the frequency of molecular alterations and will help improve the management of these patients in the future.

Stem cell transplantation study in collaboration with EPFL

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a standard therapy for many haematological diseases that unfortunately carries a high risk of complications, including aGvHD (acute graft versus host disease). Its overall incidence is between 30 and 60%, with a mortality rate of about 50%.

RNA sequencing allows the analysis of gene expression at single-cell resolution and is ideal for discovering new cellular players and pathways involved in disease processes. This pilot project, conducted in collaboration with the Swiss Federal Institute of Technology in Lausanne (EPFL, Prof. Didier Trono and Dr. Filipe Martins), will use transcriptomic data (data based on the deep RNA sequencing approach) from the sequencing of biological samples already collected and stored at the Paediatric Biobank for Research in Haematology and Oncology (BaHOP) in Geneva. Coded clinical and laboratory data from the corresponding patient records will be used to correlate the RNAseq data with the disease phenotype (i.e. an observable characteristic or trait of a disease).

Our new study on sickle cell disease

In 2020, the Swiss ethics authority authorised the recruitment of patients for one of our new studies in collaboration with the paediatric cardiology unit of the HUG (Prof. M Beghetti and Dr Duy-Anh Nguyen) aimed at detecting pulmonary abnormalities in children suffering from sickle cell disease (a blood disorder), in order to assess their risk of developing lung complications in the future. A dozen children were recruited and underwent various tests, including a dual energy chest CT (DECT - never before used in the paediatric sickle cell population), a stress test and a cardiac consultation. The results will be used to identify children at higher risk of pulmonary hypertension in adulthood, which will improve their management.

How have publications, abstracts presentations at congresses and conferences evolved?

The covid-19 crisis has not altered our ability to write scientific articles, as about 20 articles have been published in 2020 alone, on myeloid leukaemia (our **MYECHILD** project), haematopoietic stem cell transplantation, meduloblastoma and hepatoblastoma, to name but a few. This brings the total number of publications since 2011 to more than 200 articles, and 268 abstracts (research abstracts) presented at national or international conferences.

However, due to the health crisis, most congresses and conferences in Switzerland and abroad had to be cancelled. Our researchers were nevertheless able to participate in video-conference sessions that replaced them.

The BIOBANK project and its GECCOS study INTERVIEW



Denis Marino

Administrative Director of the CANSEARCH research platform in paediatric oncology and haematology at the University of Geneva

«A BIOBANK is an indispensable tool to provide tomorrow's researchers with the biological and clinical material necessary for their studies»

Denis Marino

What is a paediatric biobank and how does it work?

Like a traditional bank, a paediatric biobank is a centralised place to collect and store, not financial assets, but biological (blood, saliva), clinical and genetic material from children who have undergone cancer treatment, in order to make it available for research.

This is essential to overcome the lack of samples of proven quality for the study of paediatric oncohaematological diseases.

The establishment of the first paediatric biobank in Switzerland, financed by the CANSEARCH Foundation, started in the Paediatric Onco-Haematology Unit of the HUG ("Biobank in Paediatric Haematology and Oncology" -BAHOP), since this is where a large amount of data relating to young cancer patients was stored.

The aim is to expand the database to include material from other national and international medical centres conducting clinical pharmacogenetic studies, as well as genetic material (germline DNA), if possible from all child cancer survivors in Switzerland.

Its operation requires state-of-the-art computer software that complies with national and international legal regulations on the protection of sensitive data, biobank accreditation and sample tracking during the collection of samples. The software manages the collection, storage and distribution of samples for scientific purposes.

Who are your partners for this project and the related GECCOS study?

We are collaborating with the Childhood Cancer Registry (Prof. Claudia Kuehni) at the Institute of Social and Preventive Medicine (ISPM) of the University of Bern, which has been centralising data on children with cancer in Switzerland since the 1970s, and with the Tumour Tissue Bank in Zurich.

The aim of this project is also to link the data held by these institutions with those of the BAHOP (BIOLINK project, supported by the Swiss National Science Foundation).

The GECCOS study aims to investigate the influence of genetics on the development of complications following paediatric cancer, such as lung or hearing problems, using the biological and genetic material samples collected for the biobank project. For this purpose, two PhD students were hired by the ISPM thanks to the CANSEARCH Foundation, Dr N Waespe and Dr S Strebel.

What have been the main developments in the biobank project and the GECCOS study in 2020?

For the biobank, the contract with the chosen IT system provider was signed at the end of 2019, allowing the implementation of the biobank information management system (BIMS) which will be coordinated in collaboration with the HUG IT department (DSI) and COPAT (patient committee). The kick-off meeting took place in February 2020 and the systems were installed in the HUG IT infrastructure in June. The development of the system is ongoing.

It should be noted that for the Biobank for Paediatric Haematology and Oncology (BAHOP), we obtained the



"VITA" label from the Swiss Biobanking Platform (https://www. biobanksqan.ch/#/biobanks) at the very beginning of 2021, which certifies the quality of this institution according to various criteria.

For the GECCOS project, the collection of DNA samples from cancer survivors started in September 2019 and continued throughout 2020 with the sending of 900 saliva kits, 530 of which have already been obtained and are stored in Geneva at the Platform.

In addition, the Ethics Committee of the University of Geneva gave its approval in the summer of 2020 to the GECCOS protocol for the analysis of DNA samples taken from the saliva of these former cancer patients when they were children.

It should be noted that a study on ototoxicity (hearing problems) conducted by a PhD student attached to the Institute of Social and Preventive Medicine in Bern, with which the CANSEARCH Foundation is collaborating, has obtained support from the Swiss Cancer League, which will enable a phenotypic analysis of the DNA collected in the framework of the GECCOS study.


Liam

«I would like to continue drawing, but at home or at school and not in my hospital room»

How your **DONATIONS ARE USED**

«Concrete results that increase hope for sick children» «Clear use of your donations, because every donation counts»

The generous contributions of our donors allow us to finance the costs of our research projects, which consist mainly of the salaries of our researchers, laboratory technicians and students, the acquisition and maintenance of equipment, as well as all the material necessary for the proper conduct of our various laboratory experiments (consumables). In addition to these, our collaborators pay for participation in scientific congresses and conferences, as well as for the publication of the results of their research in various medical and scientific journals to which they regularly contribute and which attest to the scientific quality of their work.



Actions, Action Groups and CANDOS of the **CANSEARCH FOUNDATION**

«A magnificent mobilisation despite a year marked by Covid!»

Your support during the difficult months we have been through has touched us greatly: thanks to the actions and CANDOS that you carried out in 2020 in favour of child cancer research, thanks to the Foundation's Action Groups, **more than CHF 120,000** was raised, despite several events having to be cancelled at the last minute. In addition to this amount, we are of course grateful for all the generous donations we received from you during the year.

The superb crowdfunding campaign carried out by the online sales site QoQa, the temporary hosting of the foundation's office in the premises of the Bory real estate company because we could not be reintegrated into the research platform due to the social distancing, the actions of Benjie shoes and the Saturnales in favour of the foundation, or the Bridge Run for CANSEARCH were some of the events that were able to take place despite the health crisis.

We were also pleased to see the CANSEARCH flags flying on the Mont Blanc bridge on the occasion of the International Child Cancer Day on 15 February and to receive the proceeds of a magnificent sale of works of art to its employees by the UBP bank.

The sale of pots of honey in favour of the foundation, the sending of corporate greeting cards with a donation to CANSEARCH or the online fundraising launched by a young teenager also touched us greatly, as all these actions help sick children.

We are very grateful for these actions, as they all contribute to helping sick children.

We would like to express our sincere and deepest thanks for your trust and generosity.

Sat'fait faire du sport 2020

Communiqué de presse

QUI SOMMES NOUS L'association des Saturnales est créée en 1898 et depuis lors, tenue, dirigée et représentée par les troisiemes annees de la faculte de médecine de l'université de Cenève. Depuis maintenant plus de 120 ans, nous organisons des événements festifs incontournables parmi les fêtes estudiantines genevoises, ainsi que d'autres projets artitiques au cours de l'année académique. Hormis participer à la vie estudiantine, notre vocation est de soutenir 3 associations genevoises, qui benéficient des fonds récoltés à travers nos différents projets.

AUUVELAITES COVID Au vu de la situation actuelle, nous avons pour l'instant dù renoncer à organiser de grandes manifestations. Malgré cet obstacle, nous sommes en train de trouver d'autres solutions afin de récolter les fonds pour ces associations. Sensibles à l'encourgement de l'activité sportive, nous avons donc recemment decidé de mettre sur pied un evenement sportif, accessible non seulement aux étudiant es de l'UNIGE, mais également ouvert au public. Cet événement sportif a pour but de conciller activité sportive, ludisme et sécurité aniarie.

Contact : E-mail : satunales@unige.ch Site : saturnales.ch Facebook : Saturnales20 Instagram : _saturnales_ LES ASSOCIATIONS SOUTENUES C'est avec joie et fierté que nous soutenons

Octobre 2020

Cansearch (cansearch.ch)
Jaime ma planète (jmp-ch.org)
Païdos (paidos.org)



L'EVE

Les participant.e.s ont eu une semaine, du 19 au 25 octobre, pour faire le plus de sport possible parni les trois disciplines suivantes : course, vélo et/ou natation. Pour chaque kilomètre parcouru sur terre ou dans l'eau, les participant.e.s ont récuprét des dons promis au préalable par leurs partains et marraines. À la fin de la semaine, les participant.e.s ont reverse l'argent récolté à notre association qui se chargen de déverser l'intégralité de la somme aux 3 bénéficiaires. Comme toutes leurs performances sont comptabilisées sur l'application *Strava*, les meilleur.e.s athlètes recevront des prix, dont une veste de ski généreusement offerte par Mover. Grâce à un total de plus de 2000km sparouru, les participant.e.s ont permis de récolter près de 5000 CHP en faveur des associations !



BORY immobilier

réintégrer l'ensemble de son personnel Accueil de leur secrétariat général chez Bory.





February 17 - 3

Hier, QoQa s'est associé à la Fondation CANSEARCH dans le but de financer le salaire d'un chercheur en oncologie pédiatrique pendant un an. Grâce à vous, on a fait encore mieux! Alors 85'000 fois MERCI



QBLOG.QOQA.CH Votre incroyable soutien à CANSEARCH 85'000 fois MERCII A l'occasion de la journée internationale du cancer de l'enf.







PUBLISHER

CANSEARCH Foundation Chemin de Pont-Perrin 6 CH – 1226 Thônex T. +41 76 679 45 63 info@cansearch.ch www.cansearch.ch

PHOTOGRAPHERS

@ Backbone Art SA, Julien Gaspoz@ Laurence l'Huillier@ Karin Bauzin

LAYOUT COURTESY OF

Agence markette - www.markette.ch

DIGITAL COMMUNICATION

Groupe pointprod actua - www.pointprod-actua.group

MIRABAUD & CIE

Boulevard Georges-Favon 29 CH – 1204 Genève Account number : 508397 IBAN: CH10 0877 0000 0005 0839 7

POSTFINANCE

Account number: 12-189333-1 IBAN: CH12 0900 0000 1218 9333 1



FOR FURTHER INFORMATION

Patricia Legler Secretary General patricia@cansearch.ch

TO FOLLOW OUR NEWS,

follow us on our website and social networks:



Nathalie Martens Jacquet

Donor Manager

